Copyright
©The Author(s) 2024.
World J Clin Cases. Jul 26, 2024; 12(21): 4601-4608
Published online Jul 26, 2024. doi: 10.12998/wjcc.v12.i21.4601
Published online Jul 26, 2024. doi: 10.12998/wjcc.v12.i21.4601
Premedication | Post medication | Value of difference (post medication- premedication) | P value | |
Maximum diameter of myoma (n = 66, mm) | 24.05 ± 13.55 | 27.08 ± 17.3 | 3.03 | 0.017 |
Myoma volume (n = 66, mm) | 10.31 ± 15.01 | 17.15 ± 25.22 | 6.84 | 0.002 |
Uterine volume (n = 66, mm3) | 141.64 ± 98.63 | 143.71 ± 99.65 | 2.07 | 0.797 |
Maximum diameter of adenomyoma (n = 26, mm) | 42.5 ± 14.15 | 41.46 ± 19.48 | -1.04 | 0.616 |
Adenomyoma volume (n = 26, mm3) | 39.11 ± 36.22 | 37.55 ± 37.77 | -1.57 | 0.618 |
Maximum diameter of the cyst (n = 38, mm) | 33.11 ± 12.08 | 21.13 ± 15.5 | -11.97 | < 0.001 |
Volume of cysts (n = 38, mm3) | 16.22 ± 17.96 | 7.47 ± 8.36 | -8.75 | 0.002 |
Endometrial thickness (n = 66, mm) | 5.94 ± 3.59 | 4.49 ± 2.78 | -1.55 | 0.006 |
CA125 (n = 13, U/mL) | 41.6 ± 20.0 | 22.4 ± 10.9 | -19.2 | 0.002 |
- Citation: Zhang DY, Huang Y, Peng C, Zhou YF. Effect of dienogest treatment on uterine fibroid volume in patients with endometriosis or adenomyosis complicated by uterine fibroids. World J Clin Cases 2024; 12(21): 4601-4608
- URL: https://www.wjgnet.com/2307-8960/full/v12/i21/4601.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i21.4601